BR0312099A - Uso de toxina bolutìnica, bem como composição farmacêutica - Google Patents

Uso de toxina bolutìnica, bem como composição farmacêutica

Info

Publication number
BR0312099A
BR0312099A BR0312099-6A BR0312099A BR0312099A BR 0312099 A BR0312099 A BR 0312099A BR 0312099 A BR0312099 A BR 0312099A BR 0312099 A BR0312099 A BR 0312099A
Authority
BR
Brazil
Prior art keywords
bolutically
well
pharmaceutical composition
toxin use
toxin
Prior art date
Application number
BR0312099-6A
Other languages
English (en)
Inventor
Markus K Naumann
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR0312099A publication Critical patent/BR0312099A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"USO DE TOXINA BOLUTìNICA, BEM COMO COMPOSIçãO FARMACêUTICA". A presente invenção refere-se a um processo para tratar priapismo em um mamífero por administração de uma toxina botulínica.
BR0312099-6A 2002-06-26 2003-06-24 Uso de toxina bolutìnica, bem como composição farmacêutica BR0312099A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/183,221 US6776991B2 (en) 2002-06-26 2002-06-26 Methods for treating priapism
PCT/US2003/019922 WO2004002502A1 (en) 2002-06-26 2003-06-24 Botulinum toxins for treating priapism

Publications (1)

Publication Number Publication Date
BR0312099A true BR0312099A (pt) 2005-03-29

Family

ID=29779076

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312099-6A BR0312099A (pt) 2002-06-26 2003-06-24 Uso de toxina bolutìnica, bem como composição farmacêutica

Country Status (10)

Country Link
US (1) US6776991B2 (pt)
EP (1) EP1515735B1 (pt)
JP (3) JP4602762B2 (pt)
AT (1) ATE347898T1 (pt)
AU (1) AU2003243770B2 (pt)
BR (1) BR0312099A (pt)
CA (1) CA2489239C (pt)
DE (1) DE60310400T2 (pt)
ES (1) ES2278196T3 (pt)
WO (1) WO2004002502A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360712A1 (en) * 2001-12-21 2003-07-30 The Trustees Of Columbia University In The City Of New York C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
AU2003259246A1 (en) * 2002-07-29 2004-02-16 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US9511210B2 (en) * 2006-05-19 2016-12-06 The Foundry, Llc Apparatus for toxin delivery to the nasal cavity
US10052465B2 (en) 2005-07-22 2018-08-21 The Foundry, Llc Methods and systems for toxin delivery to the nasal cavity
US12433837B2 (en) 2005-07-22 2025-10-07 The Foundry, Llc Systems and methods for delivery of a therapeutic agent
EP1906923B1 (en) 2005-07-22 2018-01-24 The Foundry, LLC Systems and methods for delivery of a therapeutic agent
US20070240454A1 (en) 2006-01-30 2007-10-18 Brown David P Method and apparatus for continuous or batch optical fiber preform and optical fiber production
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
US20070283969A1 (en) * 2006-06-12 2007-12-13 Medtronic Vascular, Inc. Method of Diagnosing and Treating Erectile Dysfunction
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
CA2723806C (en) 2008-05-09 2022-05-31 Innovative Pulmonary Solutions, Inc. Systems, assemblies, and methods for treating a bronchial tree
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
JP5843777B2 (ja) 2009-10-27 2016-01-13 ホライラ， インコーポレイテッド 冷却可能なエネルギー放出アセンブリを有する送達デバイス
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
CN102711645B (zh) 2009-11-11 2016-12-28 赫莱拉公司 用于处理组织和控制狭窄的系统和装置
JP6470678B2 (ja) 2012-04-13 2019-02-13 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド ニューロンの開口分泌を阻害する化合物（ｉｉ）
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
US5439938A (en) 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
EP1488803B1 (en) 1993-12-28 2008-03-26 Allergan, Inc. Neurotoxic component of botulinum toxins for treating cervical dystonia
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ES2138740T3 (es) * 1994-05-31 2000-01-16 Allergan Inc Modificacion de toxinas de clostridium utilizadas como proteinas de transporte.
US5562899A (en) * 1995-02-28 1996-10-08 Gerber; Allen Medical prevention of lacerations to the vagina and perineum
DE69841291D1 (de) * 1997-07-15 2009-12-31 Univ Colorado Verwendung von Botulinumtoxin zur Behandlung der renitenten Blasenentleerungsstörung
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6376460B2 (en) * 1998-08-07 2002-04-23 Flinders Technologies Pty. Ltd. Method of modulating cellular activity
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
SG99857A1 (en) * 1999-11-18 2003-11-27 Univ Singapore A method of treatment and prophylaxis
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
JP4602752B2 (ja) * 2004-01-14 2010-12-22 帝人株式会社 撚糸、撚糸の製造方法および撚糸の製造装置

Also Published As

Publication number Publication date
JP2013166792A (ja) 2013-08-29
JP2005533819A (ja) 2005-11-10
ATE347898T1 (de) 2007-01-15
JP4602762B2 (ja) 2010-12-22
AU2003243770B2 (en) 2007-03-22
DE60310400D1 (de) 2007-01-25
US20040001865A1 (en) 2004-01-01
US6776991B2 (en) 2004-08-17
DE60310400T2 (de) 2007-10-11
JP2010222367A (ja) 2010-10-07
WO2004002502A1 (en) 2004-01-08
ES2278196T3 (es) 2007-08-01
AU2003243770A1 (en) 2004-01-19
EP1515735A1 (en) 2005-03-23
CA2489239C (en) 2011-10-11
CA2489239A1 (en) 2004-01-08
EP1515735B1 (en) 2006-12-13

Similar Documents

Publication Publication Date Title
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
ATE347898T1 (de) Botulinustoxine zur behandlung von priapismus
LU92278I2 (fr) Vismodegib et ses dérivés pharmaceutiquement acceptables (ERIVEDGE®)
BRPI0408476A (pt) métodos para melhorar a qualidade da pele
DK1797053T3 (da) Phenothiazinium-forbindelse til sårheling
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
ATE515514T1 (de) Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
BRPI0519243A2 (pt) mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
BR0315979A (pt) Formulação oral de toxina botulìnica e uso da mesma para tratar úlceras pépticas e doença de refluxo gastroesofágico
BRPI0411316A (pt) uso de uma toxina clostrìdica para reduzir o apetite
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
DK1638586T3 (da) Synergistisk sammensætning til behandling af diabetes mellitus
AR035293A1 (es) Composicion oftalmica.
ATE348630T1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
BR0307496A (pt) Uso de uma neurotoxina clostridiana, bem como composição farmacêutica utilizável no tratamento de um distúrbio da glândula mamária
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
ATE287267T1 (de) Kombinationstherapien mit gefässschädigender aktivität
MEP39608A (en) Novel keto-oxadiazole derivatives as cathepsin inhibitors
TW200507840A (en) Method of treating multiple myeloma
BRPI0513149A (pt) uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituìdas no tratamento de náuseas e vÈmito
DK1784205T3 (da) Strækmærkebehandling med botulinumtoksin
TW200626162A (en) Agent for controlling demodicosis
DE60322395D1 (de) Antipruritisches mittel

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.